Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:drug |
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Akero_Therapeutics
gptkb:nonalcoholic_steatohepatitis |
| https://www.w3.org/2000/01/rdf-schema#label |
efruxifermin
|
| gptkbp:indication |
gptkb:NASH
gptkb:NAFLD |
| gptkbp:mechanismOfAction |
FGF21 analog
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:synonym |
gptkb:AKR-001
|
| gptkbp:target |
fibroblast growth factor receptor
|
| gptkbp:bfsParent |
gptkb:Akero_Therapeutics
|
| gptkbp:bfsLayer |
7
|